Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.71 |
| ▸ | GLA | P06280 | 2/20 | 0.63 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 5/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | PGAM1 | P18669 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29975151 | 1.00 | KDM4E (0.71) | KDM4EGLASTING1MAOACYP19A1 | |
| Trimethylammonium SCHEMBL27716678 | 0.94 | KDM4E (0.68) | KDM4EGLASTING1MAOACYP19A1 | |
| SCHEMBL11192241 | 0.89 | ALOX5 (0.60) | KDM4EGLASTING1MAOATDP1 | |
| SCHEMBL27318901 | 0.85 | KDM4E (0.60) | KDM4EGLASTING1MAOACYP19A1 | |
| SCHEMBL10999959 | 0.84 | KDM4E (0.65) | KDM4EGLAMAOACYP19A1CYP11B1 | |
| SCHEMBL9376244 | 0.84 | STING1 (0.62) | KDM4EGLASTING1MAOAALDH1A1 | |
| SCHEMBL7140586 | 0.83 | MAOA (0.57) | KDM4EGLASTING1MAOACYP19A1 | |
| SCHEMBL20762953 | 0.83 | GLA (0.64) | KDM4EGLASTING1MAOAPTGS2 | |
| SCHEMBL9376949 | 0.82 | TTR (0.55) | KDM4EGLASTING1MAOAALDH1A1 | |
| SCHEMBL3273835 | 0.81 | KDM4E (0.77) | KDM4EGLASTING1MAOACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079510-A1 | Use of PARP-1 inhibitors for protecting tumorcidal lymphocytes from apoptosis | MAXIM PHARMACEUTICALS, INC. | 2006-04-13 | — | — | US | claimed |
| WO-2006039545-A2 | USE OF PARP-1 INHIBITORS FOR PROTECTING TUMORCIDAL LYMPHOCYTES FROM APOPTOSIS | MAXIM PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | claimed |
| CN-1217698-C | Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents | MAXIN PHARMACEUTICALS INC (US) | 2005-09-07 | — | — | CN | claimed |
| EP-1238666-B1 | Use of xanthenone-4-acetic acid in the manufacture of a medicament for the treatment of hyperproliferative disorders | HEALTH RESEARCH INC (US) | 2005-05-11 | — | — | EP | claimed |
| US-20040120926-A1 | Reactive oxygen metabolite inhibitors for use in compositions and methods of treatment | MAXIM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | claimed |
| US-6495585-B2 | Method for treating hyperproliferative tissue in a mammal | HEALTH RESEARCH, INC. | 2002-12-17 | — | — | US | claimed |
| CN-1379664-A | Activation and protection of cytotoxic lymphocytes using reactive oxygen metabolite inhibitors | MAXIM PHARMACEUTICAL INC (US) | 2002-11-13 | — | — | CN | claimed |
| US-20020128303-A1 | Method for treating hyperproliferative tissue in a mammal | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2002-09-12 | — | — | US | claimed |
| EP-1238666-A2 | Use of xanthenone-4-acetic acid in the manufacture of a medicament in the treatment of hyperproliferative disorders | HEALTH RESEARCH, INC. (US) | 2002-09-11 | — | — | EP | claimed |
| EP-1200074-A2 | USE OF DIPHENYLIODONIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC LYMPHOCYTES | Maxim Pharmaceuticals, Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| CN-1324245-A | Activation and protection of T-cells (CD4+ and CD8+) using and H2 receptor agonist and other T-cell activating agents | MAXIN PHARMACEUTICALS INC (US) | 2001-11-28 | — | — | CN | claimed |
| WO-2000010600-A9 | ACTIVATION AND PROTECTION OF T-CELLS (CD4+ AND CD8+) USING AN H¿2? RECEPTOR AGONIST AND OTHER T-CELL ACTIVATING AGENTS | MAXIM PHARM INC (US) | 2001-11-22 | — | — | WO | claimed |
| EP-1107784-A2 | ACTIVATION AND PROTECTION OF T-CELLS (CD4?+ AND CD8?+ ) USING AN H 2? RECEPTOR AGONIST AND OTHER T-CELL ACTIVATING AGENTS | Maxim Pharmaceuticals, Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| WO-2001006756-A2 | USE OF DIPHENYLIODONIUM FOR THE ACTIVATION AND PROTECTION OF CYTOTOXIC LYMPHOCYTES | MAXIM PHARMACEUTICALS, INC. (US) | 2001-01-25 | — | — | WO | claimed |
| US-6071509-A | ADMINISTERING INTERLEUKIN, INTERFERON, OR FLAVONOID | MAXIM PHARMACEUTICALS, INC. (US) | 2000-06-06 | — | — | US | claimed |
| US-6063373-A | ANTICARCER AGENT | MAXIM PHARMACEUTICALS, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-2000010600-A2 | ACTIVATION AND PROTECTION OF T-CELLS (CD4+ AND CD8+) USING AN H¿2? RECEPTOR AGONIST AND OTHER T-CELL ACTIVATING AGENTS | MAXIM PHARMACEUTICALS, INC. (US) | 2000-03-02 | — | — | WO | claimed |
| EP-0278176-B1 | Compounds having antitumour and antibacterial properties | WARNER LAMBERT CO (US) | 1994-03-09 | — | — | EP | claimed |
| US-20240181033-A1 | NANOGEL-COATED VACCINE | THE UNIVERSITY OF TOKYO (JP) | 2024-06-06 | — | — | US | disclosed |
| EP-0278176-A2 | Compounds having antitumour and antibacterial properties | WARNER-LAMBERT COMPANY (US) | 1988-08-17 | — | — | EP | disclosed |